<DOC>
	<DOCNO>NCT00861497</DOCNO>
	<brief_summary>The purpose study provide access bifeprunox patient , complete previous study bifeprunox , require continued treatment bifeprunox , treatment adequate . A purpose investigate safety side-effects bifeprunox long-term treatment .</brief_summary>
	<brief_title>Bifeprunox Extension Extension Study Patients With Schizophrenia</brief_title>
	<detailed_description>This non-controlled , open-label , flexible-dose , international multi-centre extension study . The patient population consist male female patient schizophrenia , complete open-label bifeprunox study 10206 10265 , require continued treatment bifeprunox , treatment feasible judged investigator .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients , suffer schizophrenia , complete study 10206 10265 Otherwise healthy Female patient nonchildbearing potential , nonpregnant , breastfeed woman use adequate contraception The patient must need treatment bifeprunox ( , switch another compound feasible ) Current Axis I primary psychiatric diagnosis schizophrenia Significant risk suicide and/or violent behaviour Other psychiatric , neurological behavioural disorder may interfere study conduct Substance alcohol abuse , current cannabis dependence Clinically significant physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Open-label</keyword>
	<keyword>Flexible-dose</keyword>
	<keyword>Extension</keyword>
	<keyword>Safety study</keyword>
</DOC>